Pictet Asset Management (UK)’s Theravance Biopharma TBPH Stock Holding History

Pictet Asset Management (UK)’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$3.06M	Buy	210,644 +35,351	+20%	+$664K	﹤0.01%	941
2021 Q1	$3.58M	Buy	175,293 +111,165	+173%	+$2.11M	﹤0.01%	903
2020 Q4	$1.14M	Hold	64,128	–	–	﹤0.01%	1007
2020 Q3	$948K	Buy	+64,128	New	+$1.2M	﹤0.01%	970
2018 Q3	–	Sell	-75,900	Closed	-$1.72M	–	975
2018 Q2	$1.72M	Sell	75,900 -45,500	-37%	-$1.08M	﹤0.01%	816
2018 Q1	$2.94M	Buy	+121,400	New	+$3.33M	0.01%	755
2016 Q4	–	Sell	-57,074	Closed	-$2.07M	–	864
2016 Q3	$2.07M	Hold	57,074	–	–	0.01%	728
2016 Q2	$1.31M	Sell	57,074 -22,826	-29%	-$493K	0.01%	777
2016 Q1	$1.26M	Hold	79,900	–	–	0.01%	741
2015 Q4	$1.31M	Buy	79,900 +26,000	+48%	+$413K	0.01%	767
2015 Q3	$592K	Buy	+53,900	New	+$686K	﹤0.01%	822
2014 Q3	–	Sell	-34,970	Closed	-$1.11M	–	883
2014 Q2	$1.11M	Buy	+34,970	New	+$1.05M	0.01%	783

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pictet Asset Management (UK)'s TBPH Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Theravance Biopharma (TBPH) stake by 20% in Q2 2021, buying an estimated $664K and bringing the position to 210,644 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #941.

Pictet Asset Management (UK) first reported a position in TBPH in Q2 2014 and has held it in 12 quarters since. The position peaked at $3.58M in Q1 2021. 108 funds tracked by Wall St. Rank hold TBPH as of Q2 2021.

Pictet Asset Management (UK) held 210,644 shares of Theravance Biopharma worth $3.06M as of Q2 2021.
Pictet Asset Management (UK) bought 35,351 Theravance Biopharma shares in Q2 2021, an estimated $664K.
Theravance Biopharma made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #941 holding.
Pictet Asset Management (UK) first reported a position in Theravance Biopharma in Q2 2014 and has held it in 12 quarters since.
Pictet Asset Management (UK)'s Theravance Biopharma position peaked at $3.58M in Q1 2021.
108 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.